123 related articles for article (PubMed ID: 21764318)
1. Fulminant chemical ventriculomeningitis following intrathecal liposomal cytarabine administration.
Butto A; Al-Holou WN; Junck L; Sagher O; Fletcher JJ
J Clin Neurosci; 2011 Oct; 18(10):1417-8. PubMed ID: 21764318
[TBL] [Abstract][Full Text] [Related]
2. Neurological complications after intrathecal liposomal cytarabine application in patients after allogeneic haematopoietic stem cell transplantation.
Hilgendorf I; Wolff D; Junghanss C; Kahl C; Leithaeuser M; Steiner B; Casper J; Freund M
Ann Hematol; 2008 Dec; 87(12):1009-12. PubMed ID: 18704421
[TBL] [Abstract][Full Text] [Related]
3. Liposomal cytarabine: new drug. Lymphomatous meningitis: no better than standard cytarabine.
Prescrire Int; 2006 Feb; 15(81):11-2. PubMed ID: 16548098
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis.
Bomgaars L; Geyer JR; Franklin J; Dahl G; Park J; Winick NJ; Klenke R; Berg SL; Blaney SM
J Clin Oncol; 2004 Oct; 22(19):3916-21. PubMed ID: 15459213
[TBL] [Abstract][Full Text] [Related]
5. Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adults with refractory neoplastic meningitis.
Benesch M; Sovinz P; Krammer B; Lackner H; Mann G; Schwinger W; Gadner H; Urban C
J Pediatr Hematol Oncol; 2007 Apr; 29(4):222-6. PubMed ID: 17414563
[TBL] [Abstract][Full Text] [Related]
6. Chemical meningitis related to intra-CSF liposomal cytarabine.
Durand B; Zairi F; Boulanger T; Bonneterre J; Mortier L; Le Rhun E
CNS Oncol; 2017 Oct; 6(4):261-267. PubMed ID: 29057672
[TBL] [Abstract][Full Text] [Related]
7. Neuroophthalmological side effects following intrathecal administration of liposomal cytarabine for central nervous system prophylaxis in three adolescents with acute myeloid leukaemia.
Sommer C; Lackner H; Benesch M; Sovinz P; Schwinger W; Moser A; Bergloeff J; Gruber A; Urban C
Ann Hematol; 2008 Nov; 87(11):887-90. PubMed ID: 18575860
[TBL] [Abstract][Full Text] [Related]
8. Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective study.
Benesch M; Siegler N; Hoff Kv; Lassay L; Kropshofer G; Müller H; Sommer C; Rutkowski S; Fleischhack G; Urban C
Anticancer Drugs; 2009 Oct; 20(9):794-9. PubMed ID: 19617818
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Liposomal Cytarabine in the Treatment of Neoplastic Meningitis.
Jahn F; Jordan K; Behlendorf T; Globig C; Schmoll HJ; Müller-Tidow C; Jordan B
Oncology; 2015; 89(3):137-42. PubMed ID: 25791073
[TBL] [Abstract][Full Text] [Related]
10. Intrathecal liposomal cytarabine (lipoCIT) administration in patients with leukemic or lymphomatous meningitis: efficacy and long-term safety in a single institution.
Brion A; Legrand F; Larosa F; Schillinger F; Garnache-Ottou F; Helias P; Fontan J; Heczko M; Delaby P; Daguindau E; Vuillier J; Chauchet A; Deconinck E
Invest New Drugs; 2012 Aug; 30(4):1697-702. PubMed ID: 21229289
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of liposomal cytarabine in neoplastic meningitis].
Rudà R; Leoncini B; Laguzzi E; Trevisan E; Guarneri D; Bertetto O; Soffietti R
Tumori; 2007; 93(3):suppl 4-5. PubMed ID: 17679479
[No Abstract] [Full Text] [Related]
12. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine.
Jaeckle KA; Phuphanich S; Bent MJ; Aiken R; Batchelor T; Campbell T; Fulton D; Gilbert M; Heros D; Rogers L; O'Day SJ; Akerley W; Allen J; Baidas S; Gertler SZ; Greenberg HS; LaFollette S; Lesser G; Mason W; Recht L; Wong E; Chamberlain MC; Cohn A; Glantz MJ; Gutheil JC; Maria B; Moots P; New P; Russell C; Shapiro W; Swinnen L; Howell SB
Br J Cancer; 2001 Jan; 84(2):157-63. PubMed ID: 11161370
[TBL] [Abstract][Full Text] [Related]
13. Clinical experience using intrathecal liposomal cytarabine to manage neoplastic meningitis in three patients with acute promyelocytic leukemia.
Duarte RF; Arnan M; Sánchez-Ortega I; de Llano MP; Abellán PF
Leuk Res; 2011 Jul; 35(7):e128-30. PubMed ID: 21501870
[No Abstract] [Full Text] [Related]
14. Pharmacokinetics and safety of intrathecal liposomal cytarabine in children aged <3 years.
Peyrl A; Sauermann R; Traunmueller F; Azizi AA; Gruber-Olipitz M; Gupper A; Slavc I
Clin Pharmacokinet; 2009; 48(4):265-71. PubMed ID: 19492871
[TBL] [Abstract][Full Text] [Related]
15. Liposomal cytarabine (DepoCyte) for the treatment of neoplastic meningitis.
Rueda Domínguez A; Olmos Hidalgo D; Viciana Garrido R; Torres Sánchez E
Clin Transl Oncol; 2005 Jul; 7(6):232-8. PubMed ID: 16131445
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of intrathecal liposomal cytarabine as central nervous system prophylaxis in patients with acute lymphoblastic leukemia.
Valentin A; Troppan K; Pfeilstöcker M; Nösslinger T; Linkesch W; Neumeister P
Leuk Lymphoma; 2014 Aug; 55(8):1739-42. PubMed ID: 24138308
[TBL] [Abstract][Full Text] [Related]
17. Neurological and cytological response as potential early predictors of time-to-progression and overall survival in patients with leptomeningeal carcinomatosis treated with intrathecal liposomal cytarabine: a retrospective cohort study.
Fusco JP; Castañón E; Carranza OE; Zubiri L; Martín P; Espinós J; Rodríguez J; Santisteban M; Aramendía JM; Gil-Bazo I
J Neurooncol; 2013 Dec; 115(3):429-35. PubMed ID: 24037499
[TBL] [Abstract][Full Text] [Related]
18. Intracranial hypertension following intrathecal administration of liposomal cytarabine.
Lunskens S; Lammertijn L; Deeren D; Bergmans B; Maertens J; Vandenberghe R
J Neurol; 2011 Jan; 258(1):162-3. PubMed ID: 20706845
[No Abstract] [Full Text] [Related]
19. Analysis of the role of intratecal liposomal cytarabine in the prophylaxis and treatment of central nervous system lymphomatosis: The Balearic Lymphoma Group experience.
García-Recio M; Cladera A; Bento L; Dominguez J; Ruiz de Gracia S; Sartori F; Del Campo R; García L; Ballester C; Gines J; Bargay J; Sampol A; Gutiérrez A
PLoS One; 2017; 12(6):e0179595. PubMed ID: 28665999
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma.
Garcia-Marco JA; Panizo C; Garcia ES; Deben G; Alvarez-Larran A; Barca EG; Sancho JM; Penarrubia MJ; Garcia-Cerecedo T; Garcia Vela JA
Cancer; 2009 May; 115(9):1892-8. PubMed ID: 19235254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]